RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
about
Progress toward in vivo use of siRNAs-IITranscription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin.ICAM-2 regulates vascular permeability and N-cadherin localization through ezrin-radixin-moesin (ERM) proteins and Rac-1 signalling.Mouse neuronal cells expressing exogenous bovine PRNP and simultaneous downregulation of endogenous mouse PRNP using siRNAs.Short hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse modelIn vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weightA robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors.RNA interference for improving the outcome of islet transplantation.Ionizable amphiphilic dendrimer-based nanomaterials with alkyl-chain-substituted amines for tunable siRNA delivery to the liver endothelium in vivoDelivery of siRNA to the mouse lung via a functionalized lipopolyamine.The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNADegradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma-contaminated cell culture media.Oxime ether lipids containing hydroxylated head groups are more superior siRNA delivery agents than their nonhydroxylated counterparts.Gene Silencing Mediated by siRNA-binding Fusion Proteins Is Attenuated by Double-stranded RNA-binding Domain Structure.Growth hormone modulation of EGF-induced PI3K-Akt pathway in mice liverDendrimer-Inspired Nanomaterials for the in Vivo Delivery of siRNA to Lung Vasculature.The versatility of oligonucleotides as potential therapeutics.Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.New aspects of gene-silencing for the treatment of cardiovascular diseasesNanovector delivery of siRNA for cancer therapyUse of liposomes as drug delivery vehicles for treatment of melanoma.Lipidic systems for in vivo siRNA delivery.Strategies for tumor-directed delivery of siRNA.Personalized cancer approach: using RNA interference technology.RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeuticsTargeted therapies through microRNAs: pulp or fiction?Thermosensitive liposomes for localized delivery and triggered release of chemotherapy.Delivery of RNAi therapeutics: work in progress.Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology.Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges.Delivering the promise of small ncRNA therapeutics.Therapeutic potential of siRNA and DNAzymes in cancer.Tissue engineering and microRNAs: future perspectives in regenerative medicine.Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC.Stacking up CRISPR against RNAi for therapeutic gene inhibition.The spacer arm length in cell-penetrating peptides influences chitosan/siRNA nanoparticle delivery for pulmonary inflammation treatment.Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro.Effective small interfering RNA delivery in vitro via a new stearylated cationic peptide.Biomaterials in siRNA Delivery: A Comprehensive Review.
P2860
Q28255877-724B78FC-718B-455F-AD79-3C2F6E8002DDQ28771711-2331CDFF-DEF8-467A-BDDA-5507F6ADC667Q33587422-CB4C98A4-F97D-413C-9393-C8BC5514820DQ33772925-CAD1D092-C8BF-44E1-B3F1-F405FC9BCEE8Q34049485-F6A197B6-E00B-4A2C-AEE6-57A985BA9290Q34393539-800468AB-EFBE-46E3-A845-A962B43F0802Q34706669-F8558EB3-995C-40F0-8399-27026D1FC570Q34729434-3524970A-B8EA-4643-9673-343AB0131899Q35374908-0F65FEC0-5C20-4DFA-8163-89FFF83B04BEQ35665154-40EE18D6-22B3-48F4-8732-264AF981BB69Q35764362-EDD9844A-8592-4C84-8B62-236747E6F4FAQ35867148-2B3B7CD5-1067-4E97-A1B1-2AA68959EF00Q36257158-6AC66581-95E0-4B3A-B8F0-A2EC6BE708BFQ36438289-6625F98F-FC73-4BE1-87CD-8480F3E80A21Q36739639-C013A017-D9C1-43F5-BCBA-0F99CE13D6DEQ36781516-3FF8FB13-B0D9-4D7A-AD96-71D520CA24B6Q36897394-B74DF98E-1E69-477B-9571-71A9FF58CE08Q37111373-AC5A74EA-F1A1-4F1C-BBF1-E0F9C60C3ACEQ37193000-F96BD802-EBDF-4DB0-91CE-3ADB520ABB33Q37277425-F5FE4B73-A410-4BDE-B7E4-CE05ADE07766Q37347097-702BF2C3-81FC-445D-9BD9-4A77CD7FF41AQ37406217-957000EF-2CAD-4C16-A7DB-0F669FE6329BQ37598096-0E1D4E67-D09C-4C99-B034-35AB009A5DBFQ37840092-E84F239D-40EF-4AA2-B402-9734AE226805Q37873825-33EE5B31-B14A-4EED-AE71-0EF9D6540E33Q38019046-B28AB5B3-E0A8-4F98-A4E0-044C6B8670BDQ38095966-95D362AD-9E6F-4781-B6B8-8E60CF432FA1Q38098811-4C92B58B-9928-4608-9486-9AB17781BE6EQ38160246-1277E32D-D63C-47F1-9B54-F19922F39786Q38162098-43A38F6C-520D-4E61-8D08-430B20BB0E3FQ38217461-5AFDDF51-AB82-4F10-AB7A-AC9A90B727E5Q38226666-CFCEFACC-7C5A-4E0D-B677-8FC7F3D1C7D7Q38242397-05A6B2A4-0BA8-4FF1-909E-DE1E1AFED604Q38552026-4DD5AC10-2BD9-4F9F-B031-CD26216764B2Q38692510-3DC59303-7CF6-4A2E-975A-1FA313600E73Q38811165-3B45B3D3-C106-4805-BEF3-D5484BA40723Q38819540-BB06F9C5-5305-40F1-81AF-81019B2128E7Q38871314-E74C39F9-4B48-464A-9039-38827ACC24DEQ38872103-31210274-C53F-4B17-8251-BD98C2C188F9Q38971775-742DBAB4-2781-472E-A227-BD38E92F2265
P2860
RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
RNA interference in the mouse ...... lipoplexes for cancer therapy.
@en
type
label
RNA interference in the mouse ...... lipoplexes for cancer therapy.
@en
prefLabel
RNA interference in the mouse ...... lipoplexes for cancer therapy.
@en
P2093
P2860
P356
P1433
P1476
RNA interference in the mouse ...... lipoplexes for cancer therapy.
@en
P2093
Endruschat J
Fechtner M
Kaufmann J
P2860
P2888
P304
P356
10.1038/SJ.GT.3302778
P577
2006-04-20T00:00:00Z
P5875
P6179
1007289041